Fig. 3.

A, B, BRAF WT hGBM8 and BRAF mutant hGBM9 cells were seeded at 1*10⁵ in 96-well plate in the presence of different concentrations of the BRAF inhibitor Dabrafenib and their viability was determined by the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) after 72 h. Quantitative analyses are shown as curve fitting performed by GraphPad Prism 7.0. Data are means ± SD. C, A375 melanoma cells were seeded at 5*10³ in 96-well plate in the presence of different concentrations of the same BRAFi for 72 h and then cell viability was assessed as described above. D, Effects of Dabrafenib on sphere forming efficiency by hGBM8 and hGBM9 cells